Kommentar

• Literatur

• 1 Pressemitteilung Pierre Fabre GmbH, Freiburg. Akt Urol 2024; 55: 566
• 2 Varano S, Staskin D, Frankel J. et al. Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study. Drugs Aging 2021; 38: 137-146
• 3 Staskin D, Frankel J, Varano S. et al. Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR). J Urol 2021; 205: 1421-1429
• 4 Schönburg S, Abt D. Obstruktive Blasenentleerungsstörungen – Bedeutung der Urodynamik. Akt Urol 2021; 52: 1-2
• 5 Coyne KS, Sexton CC, Irwin DE. et al. The impact of overactive bladder, in continence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008; 101: 1388-1395
• 6 Deutsche Gesellschaft für Urologie e.V. (Hrsg.). S2e-Leitlinie Diagnostik und Therapie des Benignen Prostatasyndroms (BPS), Langversion 5.0, 2023, AWMF Registernummer: 043-034. Accessed December 12, 2024 at: https://www.urologenportal.de/fachbesucher/wirueberuns/dgu/leitlinien-derdeutschen-gesellschaft-fuer-urologie.html